Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Sutter

Showing results (171-180 of 179) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 179 results.
Cancer Immunology, Immunotherapy : CII|January 1, 2005
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)Ralf G Meyer, Cedrik M Britten, Ulrike Siepmann, et al.
The Lancet. Infectious Diseases|December 3, 2014
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trialJoost H C M Kreijtz, Marco Goeijenbier, Fleur M Moesker, et al.
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trialTill Koch, Christine Dahlke, Anahita Fathi, et al.
Nature Communications|July 19, 2022
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndromeAnahita Fathi, Christine Dahlke, Verena Krähling, et al.
Frontiers in Immunology|December 3, 2021
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in RodentsBerislav Bošnjak, Ivan Odak, Joana Barros-Martins, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2021
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccinationAlina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, et al.
The Journal of Clinical Investigation|October 27, 2022
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacityChristian Meyer Zu Natrup, Alina Tscherne, Christine Dahlke, et al.
Science (New York, N.Y.)|July 25, 2020
Diverse variola virus (smallpox) strains were widespread in northern Europe in the Viking AgeBarbara Mühlemann, Lasse Vinner, Ashot Margaryan, et al.
Hepatology (Baltimore, Md.)|February 28, 2007
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicityChristine S Rollier, Glaucia Paranhos-Baccala, Ernst J Verschoor, et al.
Pageof 18

Showing results (171-180 of 179) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 179 results.
Cancer Immunology, Immunotherapy : CII|January 1, 2005
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)Ralf G Meyer, Cedrik M Britten, Ulrike Siepmann, et al.
The Lancet. Infectious Diseases|December 3, 2014
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trialJoost H C M Kreijtz, Marco Goeijenbier, Fleur M Moesker, et al.
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trialTill Koch, Christine Dahlke, Anahita Fathi, et al.
Nature Communications|July 19, 2022
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndromeAnahita Fathi, Christine Dahlke, Verena Krähling, et al.
Frontiers in Immunology|December 3, 2021
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in RodentsBerislav Bošnjak, Ivan Odak, Joana Barros-Martins, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2021
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccinationAlina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, et al.
The Journal of Clinical Investigation|October 27, 2022
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacityChristian Meyer Zu Natrup, Alina Tscherne, Christine Dahlke, et al.
Science (New York, N.Y.)|July 25, 2020
Diverse variola virus (smallpox) strains were widespread in northern Europe in the Viking AgeBarbara Mühlemann, Lasse Vinner, Ashot Margaryan, et al.
Hepatology (Baltimore, Md.)|February 28, 2007
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicityChristine S Rollier, Glaucia Paranhos-Baccala, Ernst J Verschoor, et al.
Pageof 18